1. Scrip
  2. >>Focus On Asia
  3. >>China

ESMO 23: Kelun/Merck, Hansoh ADCs Impress With Early Data In Breast Cancer

 
• By Dexter Jie Yan

In new data from Chinese developers at ESMO, Kelun/Merck’s Trop2-targeting ADC SKB264 (MK-2870) appears ready to hog the limelight from Daiichi Sankyo/AstraZeneca’s Dato-DXd, while Hansoh’s B7-H4-targeting HS-20089 is coming to the fore against its global same-class competitors. There were also new clinical results for Mabwell/Hengrui’s Nectin-4-targeting 9MW2821 and HER2-targeting SHR-A1811.

stage limelight
ESMO Congress turns spotlight on ADCs from Chinese developers • Source: Shutterstock

Chinese-made antibody-drug conjugates (ADCs) are poised to come from behind as fast-followers of their global peers on the back of impressive new Phase I and II clinical data to be orally reported at the European Society for Medical Oncology (ESMO) Congress, being held in Madrid, Spain over 20-24 October.

Key Takeaways

  • Kelun/Merck, Hansoh's ADCs, targeting Trop2 and B7-H4 respectively, shine at ESMO with impressive early-stage clinical outcomes versus global front-runners.

Breast cancer has emerged as one of the main areas of focus. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

More from Focus On Asia

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.